These biomarkers (Albumin, CRP, CXCL10, HGF, L-2Rα, IL-6, IL-8, IL-10, IL-12, IL-18, KRT18 REG3α, TNF-α, et al.)may represent novel therapeutic targets that could be inhibited by future acute GVHD-specific drugs which have been reviewed recently by Paczesny [138]. Here, REG3A is linked to acute graft versus host disease.